THE EDIT No. 004
PDRN did not begin as a skincare trend.
Its story began in medicine.
In the 1990s, research was already exploring the potential of PDRN in tissue repair and wound healing. In 1994, Placentex, an Italian medicine containing PDRN, received its first authorisation for certain connective-tissue conditions.
It was not a beauty serum. It was a medical preparation.
Over the decades that followed, PDRN and closely related polynucleotide preparations moved further into regenerative and aesthetic medicine, including injectable treatments used in some clinical settings.
And then PDRN arrived on the skincare shelf.
Today, the ingredient appears in serums, creams, eye treatments and masks, particularly within Korean skincare. What once sounded distinctly clinical has become increasingly familiar cosmetic language.
That move is not automatically a problem. Science is constantly translated into new formulations and new ways of delivering ingredients.
But when the delivery changes, the evidence needs to be considered differently too.
When an ingredient leaves the clinic and enters a cosmetic bottle, does the evidence travel with it?
That is the fine print.
PDRN stands for polydeoxyribonucleotide.
Put more simply, it is a mixture of purified DNA fragments.
Traditionally, PDRN used in medical research and applications has been derived from salmon or trout reproductive tissue, which provides DNA that can be purified and processed into fragments of varying sizes.
And size matters.
PDRN is not necessarily one uniform material. Published descriptions commonly include a broad range of molecular weights, and PDRN also sits alongside another term increasingly heard in aesthetics: PN, or polynucleotide.
The distinction between the two is not always used consistently.
Different preparations may vary in their source, fragment size, purification, concentration and formulation — all factors that can influence how a material behaves.
Newer products may use terms such as plant-derived, microbial or vegan PDRN. We will come back to those.
PDRN is not one ingredient with one outcome.
“PDRN has evidence” is an incomplete sentence.
The more useful question is:
Evidence for what, and in what form?
There is laboratory and preclinical research investigating how PDRN interacts with cells and biological pathways.
There is medical research involving areas such as wound healing and tissue repair.
There is research involving injectable PDRN and related polynucleotide preparations.
And now, there is emerging research investigating PDRN when it is applied topically to skin.
These are not interchangeable.
A result seen when a material is injected into tissue does not automatically tell us what happens when it is applied to the surface of intact skin.
Likewise, evidence involving a medical preparation cannot automatically establish the performance of a cosmetic serum carrying the same headline ingredient.
The preparation matters.
The concentration matters.
The way it reaches the skin matters.
And the outcome being measured matters.
Our skin is very good at doing one of its most important jobs: keeping things out.
For decades, researchers have used the so-called “500 Dalton rule” as a useful guide when discussing skin penetration. Smaller molecules generally have an easier time crossing the skin barrier than very large ones.
But it is a rule of thumb, not an impenetrable scientific border.
Molecular size is only part of the story. The formulation, delivery system, condition of the skin and characteristics of the material can also influence what happens after topical application.
PDRN presents an interesting challenge because its DNA fragments are considerably larger than the small molecules traditionally associated with straightforward skin penetration.
Which leads to a surprisingly simple question:
When we apply PDRN to intact skin, how much actually reaches the layers where it would need to act?
For a long time, that question has been one of the gaps between the clinical PDRN story and the cosmetic one.
Now, researchers are beginning to investigate it more directly.
In July 2026, a study published in PLOS ONE investigated a specific medium-length PDRN preparation known as PDRN-850K.
The researchers examined how this preparation behaved in laboratory and skin models and also tested a 0.1% PDRN-850K eye cream in a 28-day, randomised, double-blind, split-face study involving 31 women aged 35 to 55.
The comparison was a 0.1% retinol eye cream using the same base formula.
The researchers reported improvements in several measured periocular parameters with the PDRN formulation, including wrinkles and measures of dermal thickness and density. They also reported evidence suggesting that signals associated with this particular PDRN preparation reached viable epidermal regions in their penetration models.
The results are interesting.
But this is where reading beyond the headline matters.
The study tested one defined PDRN preparation.
At one concentration.
In one eye-cream formula.
In a relatively small group of participants.
For 28 days.
And although the study compared PDRN-850K with retinol, it does not establish that every PDRN serum will behave the same way, or that PDRN as a category is “better than retinol”.
The authors are candid about the limits. Twenty-eight days is short, and they note that early changes may partly reflect temporary hydration or plumping rather than lasting change in the skin’s structure.
The evidence that the material reached living human skin included a pilot involving a single volunteer, and the technique used cannot fully separate applied PDRN from the skin’s own nucleic acids.
There is also context worth knowing.
The paper reported no specific funding and the authors declared no conflicts of interest. It also acknowledged raw-material and technical support from suppliers, and several authors are affiliated with a skincare biotechnology company.
That does not invalidate the findings.
It simply gives us context.
So this study adds something meaningful to the topical PDRN story.
It does not finish it.
Promising evidence is still emerging evidence.
Someone can use a PDRN serum and genuinely love what it does for their skin.
PDRN rarely arrives alone. A formula may also contain humectants, niacinamide, peptides, centella, ceramides or other ingredients chosen to support hydration, comfort or the appearance of smoother skin.
So if your skin looks plumper, feels softer or appears more hydrated, that experience can be completely real.
What is harder to establish is which ingredient deserves the credit.
A finished skincare product is a formula, not an isolated laboratory ingredient. Its supporting ingredients, delivery system, texture and regular use can all shape how it performs.
A good product and a proven hero ingredient are not necessarily the same thing.
As PDRN has become more visible, so have products described as "vegan PDRN", plant-derived PDRN and PDRN from other alternative sources.
It is an area worth watching. Research is exploring non-salmon sources, including microbial production. But source matters, and two materials marketed with similar terminology should not automatically be assumed to share the same composition, fragment profile or biological behaviour.
"Vegan" tells you something important about where an ingredient did, or did not, come from. It does not, by itself, tell you how that ingredient performs.
So when a product says "vegan PDRN", the more useful questions are:
What material is actually being used?
How has it been characterised?
What evidence exists for that preparation in that formula?
The name on the front of the bottle is the beginning of the question.
Not the answer.
There is another layer worth understanding for Australian consumers.
An ingredient having a history in medicine does not automatically make every cosmetic containing that ingredient a therapeutic good.
In Australia, the Therapeutic Goods Administration (TGA) regulates therapeutic goods. Whether a product is considered a cosmetic or a therapeutic good depends on the product as a whole, including its intended purpose, presentation and the claims made about it.
Cosmetics are generally positioned around things such as appearance, cleansing, protection and keeping skin in good condition.
Therapeutic claims sit within a different regulatory framework.
That distinction matters when clinical language begins migrating onto cosmetic packaging.
A serum designed to improve the appearance of smoother or more hydrated skin is not making the same kind of claim as a product presented as healing wounds or treating a medical condition.
And an injectable used in a clinical setting should not be treated as interchangeable with a cosmetic serum simply because both are associated with PDRN.
Same buzzword.
Very different context.
For individual products, regulatory classification depends on the product as a whole rather than one ingredient in isolation.
So what should we look for when
PDRN appears on a skincare label?
Start with the claim.
Is the brand referring to research on the finished product, or research on PDRN more generally?
Then look at the evidence.
Was the research conducted on a topical product? Was PDRN injected? Was the work performed in people, on skin models or only in a laboratory?
Look at the formulation too.
Does the product tell you what kind of PDRN it contains? Is the source disclosed? Is the concentration given? Are there other well-established ingredients in the formula that could also contribute to the claimed result?
And be careful with phrases such as “clinically tested”.
Those words tell you that some form of testing occurred.
They do not tell you, on their own, how large the study was, what was measured, whether there was a comparison group, whether the finished product was tested or whether PDRN itself caused the result.
The more ambitious the promise, the more detail the evidence should provide.
PDRN may become an important topical skincare ingredient.
Recent research is beginning to ask better questions about what happens when particular PDRN preparations are applied to skin, including questions around molecular size, delivery and whether topical formulations can produce meaningful visible effects.
That is worth watching.
But enthusiasm is still moving faster than the evidence behind many of the claims surrounding the category.
That does not make PDRN meaningless.
It makes the distinction between promising and proven worth protecting.
At NKD Allure Co, an ingredient does not earn its place simply because everyone is talking about it.
Sometimes, that is exactly when we want to look closer.
~ NKD Allure Co
General information only. This article is intended for skincare education and does not constitute medical, therapeutic or legal advice.